King's College London

Research portal

Study protocol: Insight 46: a neuroscience sub-study of the MRC National Survey of Health and Development

Research output: Contribution to journalArticle

Standard

Study protocol: Insight 46 : a neuroscience sub-study of the MRC National Survey of Health and Development. / Lane, Christopher A.; Parker, Thomas D.; Cash, Dave M.; Macpherson, Kirsty; Donnachie, Elizabeth; Murray-Smith, Heidi; Barnes, Anna; Barker, Suzie; Beasley, Daniel G.; Bras, Jose; Brown, David; Burgos, Ninon; Byford, Michelle; Cardoso, M. Jorge; Carvalho, Ana; Collins, Jessica; De Vita, Enrico; Dickson, John C.; Epie, Norah; Espak, Miklos; Henley, Susie M. D.; Hoskote, Chandrashekar; Hutel, Michael; Klimova, Jana; Malone, Ian B.; Markiewicz, Pawel; Melbourne, Andrew; Modat, Marc; Schrag, Anette; Shah, Sachit; Sharma, Nikhil; Sudre, Carole H.; Thomas, David L.; Wong, Andrew; Zhang, Hui; Hardy, John; Zetterberg, Henrik; Ourselin, Sebastien; Crutch, Sebastian J.; Kuh, Diana; Richards, Marcus; Fox, Nick C.; Schott, Jonathan M.

In: BMC Neurology, Vol. 17, 75, 18.04.2017.

Research output: Contribution to journalArticle

Harvard

Lane, CA, Parker, TD, Cash, DM, Macpherson, K, Donnachie, E, Murray-Smith, H, Barnes, A, Barker, S, Beasley, DG, Bras, J, Brown, D, Burgos, N, Byford, M, Cardoso, MJ, Carvalho, A, Collins, J, De Vita, E, Dickson, JC, Epie, N, Espak, M, Henley, SMD, Hoskote, C, Hutel, M, Klimova, J, Malone, IB, Markiewicz, P, Melbourne, A, Modat, M, Schrag, A, Shah, S, Sharma, N, Sudre, CH, Thomas, DL, Wong, A, Zhang, H, Hardy, J, Zetterberg, H, Ourselin, S, Crutch, SJ, Kuh, D, Richards, M, Fox, NC & Schott, JM 2017, 'Study protocol: Insight 46: a neuroscience sub-study of the MRC National Survey of Health and Development', BMC Neurology, vol. 17, 75. https://doi.org/10.1186/s12883-017-0846-x

APA

Lane, C. A., Parker, T. D., Cash, D. M., Macpherson, K., Donnachie, E., Murray-Smith, H., ... Schott, J. M. (2017). Study protocol: Insight 46: a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology, 17, [75]. https://doi.org/10.1186/s12883-017-0846-x

Vancouver

Lane CA, Parker TD, Cash DM, Macpherson K, Donnachie E, Murray-Smith H et al. Study protocol: Insight 46: a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology. 2017 Apr 18;17. 75. https://doi.org/10.1186/s12883-017-0846-x

Author

Lane, Christopher A. ; Parker, Thomas D. ; Cash, Dave M. ; Macpherson, Kirsty ; Donnachie, Elizabeth ; Murray-Smith, Heidi ; Barnes, Anna ; Barker, Suzie ; Beasley, Daniel G. ; Bras, Jose ; Brown, David ; Burgos, Ninon ; Byford, Michelle ; Cardoso, M. Jorge ; Carvalho, Ana ; Collins, Jessica ; De Vita, Enrico ; Dickson, John C. ; Epie, Norah ; Espak, Miklos ; Henley, Susie M. D. ; Hoskote, Chandrashekar ; Hutel, Michael ; Klimova, Jana ; Malone, Ian B. ; Markiewicz, Pawel ; Melbourne, Andrew ; Modat, Marc ; Schrag, Anette ; Shah, Sachit ; Sharma, Nikhil ; Sudre, Carole H. ; Thomas, David L. ; Wong, Andrew ; Zhang, Hui ; Hardy, John ; Zetterberg, Henrik ; Ourselin, Sebastien ; Crutch, Sebastian J. ; Kuh, Diana ; Richards, Marcus ; Fox, Nick C. ; Schott, Jonathan M. / Study protocol: Insight 46 : a neuroscience sub-study of the MRC National Survey of Health and Development. In: BMC Neurology. 2017 ; Vol. 17.

Bibtex Download

@article{8f5194e05b674ece8dae7c3b8bd938a5,
title = "Study protocol: Insight 46: a neuroscience sub-study of the MRC National Survey of Health and Development",
abstract = "Background: Increasing age is the biggest risk factor for dementia, of which Alzheimer's disease is the commonest cause. The pathological changes underpinning Alzheimer's disease are thought to develop at least a decade prior to the onset of symptoms. Molecular positron emission tomography and multi-modal magnetic resonance imaging allow key pathological processes underpinning cognitive impairment - including β-amyloid depostion, vascular disease, network breakdown and atrophy - to be assessed repeatedly and non-invasively. This enables potential determinants of dementia to be delineated earlier, and therefore opens a pre-symptomatic window where intervention may prevent the onset of cognitive symptoms.Methods/design: This paper outlines the clinical, cognitive and imaging protocol of {"}Insight 46{"}, a neuroscience sub-study of the MRC National Survey of Health and Development. This is one of the oldest British birth cohort studies and has followed 5362 individuals since their birth in England, Scotland and Wales during one week in March 1946. These individuals have been tracked in 24 waves of data collection incorporating a wide range of health and functional measures, including repeat measures of cognitive function. Now aged 71years, a small fraction have overt dementia, but estimates suggest that ~1/3 of individuals in this age group may be in the preclinical stages of Alzheimer's disease. Insight 46 is recruiting 500 study members selected at random from those who attended a clinical visit at 60-64years and on whom relevant lifecourse data are available. We describe the sub-study design and protocol which involves a prospective two time-point (0, 24month) data collection covering clinical, neuropsychological, β-amyloid positron emission tomography and magnetic resonance imaging, biomarker and genetic information. Data collection started in 2015 (age 69) and aims to be completed in 2019 (age 73). Discussion: Through the integration of data on the socioeconomic environment and on physical, psychological and cognitive function from 0 to 69years, coupled with genetics, structural and molecular imaging, and intensive cognitive and neurological phenotyping, Insight 46 aims to identify lifetime factors which influence brain health and cognitive ageing, with particular focus on Alzheimer's disease and cerebrovascular disease. This will provide an evidence base for the rational design of disease-modifying trials.",
keywords = "Ageing, Alzheimer's disease, Birth cohort, Cognition, Epidemiology, Genetics, Life course, Magnetic resonance imaging, Positron emission tomography, Vascular disease",
author = "Lane, {Christopher A.} and Parker, {Thomas D.} and Cash, {Dave M.} and Kirsty Macpherson and Elizabeth Donnachie and Heidi Murray-Smith and Anna Barnes and Suzie Barker and Beasley, {Daniel G.} and Jose Bras and David Brown and Ninon Burgos and Michelle Byford and Cardoso, {M. Jorge} and Ana Carvalho and Jessica Collins and {De Vita}, Enrico and Dickson, {John C.} and Norah Epie and Miklos Espak and Henley, {Susie M. D.} and Chandrashekar Hoskote and Michael Hutel and Jana Klimova and Malone, {Ian B.} and Pawel Markiewicz and Andrew Melbourne and Marc Modat and Anette Schrag and Sachit Shah and Nikhil Sharma and Sudre, {Carole H.} and Thomas, {David L.} and Andrew Wong and Hui Zhang and John Hardy and Henrik Zetterberg and Sebastien Ourselin and Crutch, {Sebastian J.} and Diana Kuh and Marcus Richards and Fox, {Nick C.} and Schott, {Jonathan M.}",
year = "2017",
month = "4",
day = "18",
doi = "10.1186/s12883-017-0846-x",
language = "English",
volume = "17",
journal = "BMC Neurology",
issn = "1471-2377",
publisher = "BioMed Central",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Study protocol: Insight 46

T2 - a neuroscience sub-study of the MRC National Survey of Health and Development

AU - Lane, Christopher A.

AU - Parker, Thomas D.

AU - Cash, Dave M.

AU - Macpherson, Kirsty

AU - Donnachie, Elizabeth

AU - Murray-Smith, Heidi

AU - Barnes, Anna

AU - Barker, Suzie

AU - Beasley, Daniel G.

AU - Bras, Jose

AU - Brown, David

AU - Burgos, Ninon

AU - Byford, Michelle

AU - Cardoso, M. Jorge

AU - Carvalho, Ana

AU - Collins, Jessica

AU - De Vita, Enrico

AU - Dickson, John C.

AU - Epie, Norah

AU - Espak, Miklos

AU - Henley, Susie M. D.

AU - Hoskote, Chandrashekar

AU - Hutel, Michael

AU - Klimova, Jana

AU - Malone, Ian B.

AU - Markiewicz, Pawel

AU - Melbourne, Andrew

AU - Modat, Marc

AU - Schrag, Anette

AU - Shah, Sachit

AU - Sharma, Nikhil

AU - Sudre, Carole H.

AU - Thomas, David L.

AU - Wong, Andrew

AU - Zhang, Hui

AU - Hardy, John

AU - Zetterberg, Henrik

AU - Ourselin, Sebastien

AU - Crutch, Sebastian J.

AU - Kuh, Diana

AU - Richards, Marcus

AU - Fox, Nick C.

AU - Schott, Jonathan M.

PY - 2017/4/18

Y1 - 2017/4/18

N2 - Background: Increasing age is the biggest risk factor for dementia, of which Alzheimer's disease is the commonest cause. The pathological changes underpinning Alzheimer's disease are thought to develop at least a decade prior to the onset of symptoms. Molecular positron emission tomography and multi-modal magnetic resonance imaging allow key pathological processes underpinning cognitive impairment - including β-amyloid depostion, vascular disease, network breakdown and atrophy - to be assessed repeatedly and non-invasively. This enables potential determinants of dementia to be delineated earlier, and therefore opens a pre-symptomatic window where intervention may prevent the onset of cognitive symptoms.Methods/design: This paper outlines the clinical, cognitive and imaging protocol of "Insight 46", a neuroscience sub-study of the MRC National Survey of Health and Development. This is one of the oldest British birth cohort studies and has followed 5362 individuals since their birth in England, Scotland and Wales during one week in March 1946. These individuals have been tracked in 24 waves of data collection incorporating a wide range of health and functional measures, including repeat measures of cognitive function. Now aged 71years, a small fraction have overt dementia, but estimates suggest that ~1/3 of individuals in this age group may be in the preclinical stages of Alzheimer's disease. Insight 46 is recruiting 500 study members selected at random from those who attended a clinical visit at 60-64years and on whom relevant lifecourse data are available. We describe the sub-study design and protocol which involves a prospective two time-point (0, 24month) data collection covering clinical, neuropsychological, β-amyloid positron emission tomography and magnetic resonance imaging, biomarker and genetic information. Data collection started in 2015 (age 69) and aims to be completed in 2019 (age 73). Discussion: Through the integration of data on the socioeconomic environment and on physical, psychological and cognitive function from 0 to 69years, coupled with genetics, structural and molecular imaging, and intensive cognitive and neurological phenotyping, Insight 46 aims to identify lifetime factors which influence brain health and cognitive ageing, with particular focus on Alzheimer's disease and cerebrovascular disease. This will provide an evidence base for the rational design of disease-modifying trials.

AB - Background: Increasing age is the biggest risk factor for dementia, of which Alzheimer's disease is the commonest cause. The pathological changes underpinning Alzheimer's disease are thought to develop at least a decade prior to the onset of symptoms. Molecular positron emission tomography and multi-modal magnetic resonance imaging allow key pathological processes underpinning cognitive impairment - including β-amyloid depostion, vascular disease, network breakdown and atrophy - to be assessed repeatedly and non-invasively. This enables potential determinants of dementia to be delineated earlier, and therefore opens a pre-symptomatic window where intervention may prevent the onset of cognitive symptoms.Methods/design: This paper outlines the clinical, cognitive and imaging protocol of "Insight 46", a neuroscience sub-study of the MRC National Survey of Health and Development. This is one of the oldest British birth cohort studies and has followed 5362 individuals since their birth in England, Scotland and Wales during one week in March 1946. These individuals have been tracked in 24 waves of data collection incorporating a wide range of health and functional measures, including repeat measures of cognitive function. Now aged 71years, a small fraction have overt dementia, but estimates suggest that ~1/3 of individuals in this age group may be in the preclinical stages of Alzheimer's disease. Insight 46 is recruiting 500 study members selected at random from those who attended a clinical visit at 60-64years and on whom relevant lifecourse data are available. We describe the sub-study design and protocol which involves a prospective two time-point (0, 24month) data collection covering clinical, neuropsychological, β-amyloid positron emission tomography and magnetic resonance imaging, biomarker and genetic information. Data collection started in 2015 (age 69) and aims to be completed in 2019 (age 73). Discussion: Through the integration of data on the socioeconomic environment and on physical, psychological and cognitive function from 0 to 69years, coupled with genetics, structural and molecular imaging, and intensive cognitive and neurological phenotyping, Insight 46 aims to identify lifetime factors which influence brain health and cognitive ageing, with particular focus on Alzheimer's disease and cerebrovascular disease. This will provide an evidence base for the rational design of disease-modifying trials.

KW - Ageing

KW - Alzheimer's disease

KW - Birth cohort

KW - Cognition

KW - Epidemiology

KW - Genetics

KW - Life course

KW - Magnetic resonance imaging

KW - Positron emission tomography

KW - Vascular disease

UR - http://www.scopus.com/inward/record.url?scp=85018500875&partnerID=8YFLogxK

U2 - 10.1186/s12883-017-0846-x

DO - 10.1186/s12883-017-0846-x

M3 - Article

C2 - 28420323

AN - SCOPUS:85018500875

VL - 17

JO - BMC Neurology

JF - BMC Neurology

SN - 1471-2377

M1 - 75

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454